TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 1 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $70,886 | -23.8% | 7,929 | +31.0% | 0.00% | -33.3% |
| Q2 2023 | $92,974 | +130849.3% | 6,053 | +92.8% | 0.00% | +50.0% |
| Q1 2023 | $71 | -36.6% | 3,139 | -41.2% | 0.00% | -60.0% |
| Q4 2022 | $112 | -99.9% | 5,336 | -34.1% | 0.01% | +66.7% |
| Q3 2022 | $199,000 | -58.6% | 8,099 | -59.2% | 0.00% | -72.7% |
| Q2 2022 | $481,000 | +74.9% | 19,861 | +85.8% | 0.01% | +266.7% |
| Q1 2022 | $275,000 | +21.7% | 10,690 | +46.4% | 0.00% | -25.0% |
| Q4 2021 | $226,000 | +69.9% | 7,301 | +33.3% | 0.00% | +33.3% |
| Q3 2021 | $133,000 | +84.7% | 5,479 | +10.6% | 0.00% | +50.0% |
| Q2 2021 | $72,000 | +22.0% | 4,956 | +110.9% | 0.00% | +100.0% |
| Q1 2021 | $59,000 | +40.5% | 2,350 | +51.5% | 0.00% | 0.0% |
| Q4 2020 | $42,000 | – | 1,551 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 875,221 | $19,683,720 | 7.52% |
| Deep Track Capital, LP | 6,147,268 | $138,252,057 | 5.68% |
| Kynam Capital Management, LP | 1,563,595 | $35,165,252 | 4.54% |
| GREAT POINT PARTNERS LLC | 1,003,000 | $22,557,470 | 4.43% |
| ARMISTICE CAPITAL, LLC | 7,148,000 | $160,758,520 | 2.32% |
| HighVista Strategies LLC | 121,834 | $2,740,047 | 2.23% |
| MPM BioImpact LLC | 313,642 | $7,053,809 | 1.83% |
| Sofinnova Investments, Inc. | 1,263,721 | $28,421,085 | 1.82% |
| Octagon Capital Advisors LP | 495,000 | $11,132,550 | 1.60% |
| SECTORAL ASSET MANAGEMENT INC | 358,613 | $8,065,206 | 1.55% |